Respiratory syncytial virus immune globulin intravenous: Indications for use

Pediatrics

Volumn 99, Issue 4, 1997, Pages 645-650

  Halsey, N A ^a   Abramson, J S ^a   Chesney, P J ^a   Fisher, M C ^a   Gerber, M A ^a   Gromisch, D S ^a   Kohl, S ^a   Marcy, S M ^a   Murray, D L ^a   Overturf, G D ^a   Whitley, R J ^a   Yogev, R ^a   Peter, G ^a   Hall, C B ^a   Overall J C , Jr ^a   Berkelman, R ^a   Orenstein, W A ^a   Breiman, R ^a   Hardegree, M C ^a   Jacobs, R F ^a   MacDonald, N E ^a   Rabinovich, N R ^a   Oh, W ^a   Blackmon, L R ^a   Fanaroff, A A ^a   Kirkpatrick, B V ^a   MacDonald, H M ^a   Miller, C A ^a   Papile L , A ^a   Shoemaker, C T ^a   Speer, M E ^a   Johnson, P ^a   Greene M F , Jr ^a   McMillan, D D ^a   Rowley, D ^a   Wright, L L ^a   Langer, J C ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS IMMUNOGLOBULIN; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CONGENITAL HEART DISEASE; HIGH RISK POPULATION; HUMAN; LUNG DYSPLASIA; OXYGEN THERAPY; PREMATURITY; PRIORITY JOURNAL; PUBLIC HEALTH; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SAFETY; VIRUS INFECTION;

BRONCHOPULMONARY DYSPLASIA; COST-BENEFIT ANALYSIS; HEART DEFECTS, CONGENITAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 0009507060     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Groothuis JR, Simoes EAF, Levin MJ, RSVIG Study Croup. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993;329:1524-1530
2. Connor E, PREVENT Study Group. Reduction of RSV hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997;99:93-99
3. American Academy of Pediatrics, Committee on Infectious Diseases. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics. 1996;97:137-140
4. Hay JW, Ernst RL, Meissner HC. Respiratory syncytial virus immune globulin: a cost-effectiveness analysis. Am J Managed Care. 1996;2:851-861
5. Ventura SJ, Martin JA, Taffel SM, Mathews TJ, Clarke SC. Advance report of final natality statistics 1993. Vital Stat Rep. 1995;44(suppl 3):1-86
6. Meissner HC, Economic impact of viral respiratory disease in children. J Pediatr. 1994;124:S17-S21
7. American Academy of Pediatrics, Committee on Infectious Diseases. Peter G, ed. 1994 Red Book. Report of the Committee on Infectious Diseases. 23rd ed. Elk Grove Village, IL: American Academy of Pediatrics; 1994
8. Clemens J, Brenner R, Malla R, Tafari N, Lowe C. Evaluating new vaccines for developing countries; efficacy or effectiveness? JAMA. 1996;275:390-397
9. American Academy of Pediatrics, Committee on Infectious Diseases. Use of ribavirin in the treatment of respiratory syncytial virus infection. Pediatrics. 1993;92:501-504
10. Groothuis JR, Levin MJ, Rodriguez W, RSVIG Study Group. Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. Antimicrob Agents Chemother. 1991;35:1469-1473
11. Meissner HC, Fulton DR, Groothuis JR, et al. Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob Agents Chemother. 1993;37:1655-1658
12. Siber GR, Leszczynski J, Pena-Cruz V, et al. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J Infect Dis. 1992;165: 456-463
13. Siber GR, Leombruno D, Leszczynski J, et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis. 1994; 169:1368-1373
14. Graham BS, Davis TH, Tang Y-W, Gruber WC. Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with respiratory syncytial virus-specific immune serum. Pediatr Res. 1993;34: 167-172
15. Sami IR, Piazza FM, Johnson SA, et al. Systemic immunoprophylaxis of nasal respiratory syncytial virus infection in cotton rats. J Infect Dis. 1995;171:440-443
16. Hemming VG, Prince GA, Groothuis JR, Siber GR. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev. 1995;8:22-33
17. Groothuis JR, Simoes EAF, Hemming VG, RSVIG Study Group. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics. 1995;95: 463-467
18. Simoes EAF, Groothuis JR, Tristram DA, et al. Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children. J Pediatr. 1996;129:214-219
19. Simoes EAF, Sondheimer HM, Meissner HC, Welliver RC, Groothuis JR, RSVIG Study Group. Respiratory syncytial virus immunoglobulin as prophylaxis against respiratory syncytial virus in children with congenital heart disease. Pediatr Res. 1996;39:113A. Abstract
20. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics. 1988; 82:199-203
21. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics. 1991; 88:527-532
22. Wang EEL, Law B, Stephens D, Members of the PICNIC. Pediatric investigators collaborative network on infections in Canada (PICNIC) prospective study of risk factors with respiratory syncytial viral lower respiratory tract infection. J Pediatr. 1995;126:212-219
23. Smith DW, Frankel LR, Mathers LH, Tang ATS, Ariagno RL, Prober CG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med. 1991;325:24-29
24. Abman SH, Groothuis JR. Pathophysiology and treatment of bronchopulmonary dysplasia. Pediatr Clin North Am. 1994;41:277-315
25. Hall CB, Geiman JM, Douglas RG, Meagher MP. Control of nosocomial respiratory syncytial virus infections. Pediatrics. 1978;62:728-732
26. Hall CB, Powell KR, MacDonald NE, et al. Respiratory syncytial virus infection in children with compromised immune function. N Engl J Med. 1986;315:77-81
27. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial virus infection in infants with congenital heart disease. N Engl J Med. 1982;307:397-399
28. Madge P, Paton JY, McColl JH, Mackie PK. Prospective controlled study of four infection control procedures to prevent nosocomial infection with respiratory syncytial virus. Lancet. 1992;340:1079-1083
29. Gilchrist S, Torok TJ, Gary HE Jr, Alexander JP, Anderson LJ. National surveillance for respiratory syncytial virus, United States, 1985-1990. J Infect Dis. 1994;170:986-990
30. Török TJ, Clarke MW, Holman RC, Anderson LJ. Temporal and spatial trends in respiratory syncytial virus activity in the United States, 1990-1996. Presented at RSV After 40 Years: An Anniversary Symposium; November 9-12, 1996; Charleston, SC. Abstract
31. Hemming VG, Rodriguez W, Kim HW, et al. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob Agents Chemother. 1987;31:1882-1886
32. Rodriguez WJ, Gruber WC, Groothuis J, Rosas AJ, Lepow M, Hemming V, RSVIG Study Group. Respiratory syncytial virus immune human globulin (RSV Ig) as treatment of RSV lower respiratory tract infections in children. Pediatr Res. 1996;39:183A. Abstract
33. Whimbey E, Champlin RE, Englund JA, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant. 1995;16:393-399
34. Piazza FM, Johnson SA, Ottolini MG, et al. Immunotherapy of respiratory syncytial virus infection in cotton rats (Sigmodon fulviventer) using IgG in a small-particle aerosol. J Infect Dis. 1992;166:1422-1424
35. Weltzin R, Hsu SA, Mittler S, Georgakopoulos K, Monath TP. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrob Agents Chemother. 1994;38:2785-2791
36. Graham BS, Tang Y-W, Gruber WC. Topical immunoprophylaxis of respiratory syncytial virus (RSV)-challenged mice with RSV-specific immune globulin. J Infect Dis. 1995;171:1468-1474
37. Weltzin R, Traina-Dorge V, Soike K, et al. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis. 1996;174:256-261
38. Rimensberger PC, Schaad UB. Clinical experience with aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants. Pediatr Infect Dis J. 1994;13:328-330
39. Mills J. Immunotherapy and immunoprophylaxis of respiratory syncytial virus infections. Curr Opin Infect Dis. 1995;8:473-478
40. Crowe JE Jr, Murphy BR, Chanock RM, Williamson RA, Barbas CF III, Burton DR. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci USA. 1994;91:1386-1390
41. Hall CB. Prospects for a respiratory syncytial virus vaccine. Science. 1994;265:1393-1394
42. Anderson LJ, Heilman CA. Protective and disease-enhancing immune responses to respiratory syncytial virus vaccine. J Infect Dis. 1995;171:1-7
43. Murphy BR, Hall SL, Kulkarni AB, et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 1994;32:13-36
44. Englund JA. Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody. Pediatr Infect Dis J. 1994; 13:449-453